CytRx Corporation announced the appointment of Shanta Chawla, M.D. as Vice President, Clinical Development. Dr. Chawla has more than 13 years of clinical research, operations and development experience, with a focus on oncology therapeutics. From 2001 to 2013 Dr. Chawla was at Spectrum Pharmaceuticals, most recently as Vice President, Clinical Research and Development, where her expertise included selecting clinical trial sites and principal investigators, establishing protocols with the FDA and key opinion leaders, preparing FDA filings and project team management.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.52 USD | +6.78% | +9.57% | +93.85% |
04/06 | LadRx Corporation and ImmunityBio, Inc. Mutually Agree to Terminate Aldoxorubicin License | CI |
15/05 | LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
+93.85% | 1.25M | |
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+43.96% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
-4.47% | 28.7B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B |
- Stock Market
- Equities
- LADX Stock
- News LadRx Corporation
- Cytrx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development